Efficacy and Safety of Clascoterone Cream 1% in Facial Ac... | NCT06403501

NCT06403501

Protocol Section

Identification Module

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Status Module

Design Module

Interventional Study Design

Biospecimen

No data available

No data is available for this block.

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Clascoterone Cream 1%	Experimental	Clascoterone Cream 1% (Winlevi)	Drug: Clascoterone
Vehicle cream	Placebo Comparator	Vehicle cream manufactured to mimic look and feel of Clascoterone Cream 1% but without the active ingredient.	Drug: Vehicle cream

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Clascoterone	Drug	Clascoterone Cream 1% (Winlevi) is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.	Clascoterone Cream 1%

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Percentage of Participants Achieving Success in Investigator's Global Assessment (IGA)	Percentage of subjects in each treatment group achieving "success" at Week 12, with "success" defined as an IGA score of "clear (score=0)" or "almost clear (score=1)" and at least a two-point reduction in IGA compared to Baseline.	Week 12
Change From Baseline in Non-inflammatory Lesion (NIL) Counts	Absolute change from Baseline in non-inflammatory lesion counts in each treatment group at Week 12.	Week 12
Change From Baseline in Inflammatory Lesion (IL) Counts	Absolute change from Baseline in inflammatory lesion counts in each treatment group at Week 12.	Week 12

Secondary Outcomes

Measure	Description	Time Frame
Change From Baseline in Total Lesion Counts	Absolute change from Baseline in total lesions counts in each treatment group at Week 12.	Week 12
Percent Change From Baseline in Total Lesion Counts

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Diagnosed with facial acne vulgaris (which includes the nose) from moderate to severe, has an Investigator's Global Assessment (IGA) score of 3 or 4; with at least 30 to a maximum of 75 inflammatory lesions (papules, pustules, and nodules) and 30 to a maximum of 100 non-inflammatory lesions (open and closed comedones);
Male or female, 12 years of age or older;
Subjects aged 18 years or older are required to provide informed consent and sign the written informed consent. A subject under 18 years of age must provide written informed assent and be accompanied by the parent or legal guardian at the time of consent signing.

Exclusion Criteria:

Subject has greater than two (2) facial nodules;
Subject has any skin pathology or condition that could interfere with the investigator's clinical evaluation of the investigational drug;
Subject has used topical and systemic anti-acne medications or therapies;
Subject has received hormonal therapy for acne treatment;
Subject has used a skincare product with acne removal effect;
Subject has other serious underlying diseases such as mental illness or malignant tumors;
Subject has any of the clinically significant laboratory test indicators at screening;
Subject has known hypersensitivity or previous allergic reaction to multiple drugs, or any of the active or inactive components of the test articles;
Subject engaged in drug abuse or excessive alcohol intake;
Subject has uncontrolled hypertension; Subject has poorly controlled diabetes;
Subject is pregnant, lactating, or is planning to become pregnant during the study (both male and female); subject has positive pregnancy test result; subject is unable to practice highly effective contraception methods during the trial and within 3 months after the end of the trial;
Subject is currently enrolled or was enrolled in other clinical trials within 3 months prior to the initiation of treatment;
Subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this clinical trial.

ID	Term
D017486	Acneiform Eruptions
D012871	Skin Diseases
D017437	Skin and Connective Tissue Diseases
D012625	Sebaceous Gland Diseases